Loss of EphA2 receptor tyrosine kinase reduces Apc Min/+ tumorigenesis

International Journal of Cancer

Volumn 124, Issue 6, 2009, Pages 1366-1371

  Bogan, Christina ^a   Chen, Jin ^b   O'Sullivan, M Gerard ^c   Cormier, Robert T ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Apc; Colon cancer; EphA2; Min; Receptor tyrosine kinase

Indexed keywords

EPHRIN RECEPTOR A2; MESSENGER RNA; PROTEIN TYROSINE KINASE; PRIMER DNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOGENESIS; COLON TUMOR; CONTROLLED STUDY; EXPERIMENTAL MODEL; FEMALE; GENE EXPRESSION PROFILING; GENE FUNCTION; IMMUNOHISTOCHEMISTRY; INTESTINE CANCER; KNOCKOUT MOUSE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SMALL INTESTINE TUMOR; TISSUE DISTRIBUTION; UPREGULATION; ANIMAL; BREAST TUMOR; C57BL MOUSE; CHROMOSOME 1; CHROMOSOME MAP; CYTOLOGY; DISEASE COURSE; GENETICS; GENOTYPE; HUMAN; INTESTINE; METASTASIS; MUTATION; NEOPLASM; PATHOLOGY; POLYMERASE CHAIN REACTION;

ANIMALS; BREAST NEOPLASMS; CHROMOSOME MAPPING; CHROMOSOMES, HUMAN, PAIR 1; DISEASE PROGRESSION; DNA PRIMERS; FEMALE; GENOTYPE; HUMANS; INTESTINES; MALE; MICE; MICE, INBRED C57BL; MUTATION; NEOPLASM METASTASIS; NEOPLASMS; POLYMERASE CHAIN REACTION; RECEPTOR, EPHA2;

EID: 60549086460     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.24083     Document Type: Article

References (61)

1. Brantiey-Sieders DM, Chen J. Eph receptor tyrosine kinases in angiogenesis: from development to disease. Angiogenesis 2004;7:17-28.
2. Dodelet V, Pasquale E. Eph receptors and ephrin ligands: embryogenesis to tumorigenesis. Oncogene 2000;19:5614-19.
3. Kullander K, Klein R, Mechanisms and functions of Eph and ephrin signaling. Nat Rev Mol Cell Biol 2002;3:475-86.
4. Murai KK, Pasquale EB. 'Eph'ective signaling: forward, reverse and crosstalk. J Cell Sci 2003; 116:2823-32.
5. Pasquale EB. Eph receptor signaling casts a wide net on cell behavior. Nat Rev Mol Cell Biol 2005;6:462-75.
6. Poliakov A, Cotrina M, Wilkinson DG. Diverse roles of eph receptors and ephrins in the regulation of cell migration and tissue assembly. Dev Cell 2004;7:465-80.
7. Brantiey-Sieders DM, Caughron J, Hicks D, Pozzi A, Ruiz JC, Chen J. EphA2 receptor tyrosine kinase regulates endothelial cell migration and vascular assembly through phosphoinositide3-kinase-raediated Racl GTPase activation. J Cell Sci 2004;117:2037-49.
8. Cheng N, Brantley DM, Chen J. The ephrins and Eph receptors in angiogenesis. Cytokine Growth Factor Rev 2002;13:75-85.
9. Brantiey-Sieders D, Parker M, Chen J. Eph receptor tyrosine kinases in tumor and tumor microenvironment. Curr Pharm Des 2004; 10; 3431 -42.
10. Hafner C, Schmitz G, Meyer S, Bataille F, Hau P, Langmann T, Dietmaier W, Landthaler M, Vogt T. Differential gene expression of Eph receptors and ephrins in benign human tissues and cancers. Clin Chem 2004;50:490-9.
11. Ireton RC, Chen J. EphA2 receptor tyrosine kinase as a promising target for cancer therapeutics. Curr Cancer Drug Targets 2005;5:149-57.
12. Kinch MS, Carles-Kinch K. Overexpression and functional alterations of the EphA2 tyrosine kinase in cancer. Clin Exp Metastasis 2003; 20:59-68.
13. Ogawa K, Pasqualini R, Lindberg RA, Kain R, Freeman AL, Pasquale EB. The ephrin-Al ligand and its receptor. Eph A2, are expressed during tumor neovascularization. Oncogene 2000; 19:6043-52.
14. Surawska H, Ma PC, Salgia R. The role of ephrins and Eph receptors in cancer. Cytokine Growth Factor Rev 2004; 15:419-33.
15. Nakamoto M, Bergemann AD. Diverse roles for the Eph family of receptor tyrosine kinases in carcinogenesis. Microsc Res Tech 2002; 59:58-67.
16. Brantiey-Sieders DM, Fang WB, Hwang Y, Hicks D, Chen J. Ephrin-Al facilitates mammary tumor metastasis through an angiogenesis-dependent mechanism mediated by EphA receptor and vascular endothelial growth factor in mice. Cancer Res 2006;66:10315-24.
17. Brantiey-Sieders DM, Zhuang G, Hicks D, Fang WB, Hwang Y, Gates JMM, Coffman K, Jackson D, Bruckheimer E, Muraoka-Cook RS, Chen J. The receptor tyrosine kinase EphA2 promotes mammary adenocarcinoma tumorigenesis and metastatic progression in mice by amplifying ErbB2 signaling. J Clin Invest 2008; 118:64-78.
18. Zelinski DP, Zantek ND, Stewart JC, Irizarry AR, Kinch MS. EphA2 overexpression causes tumorigenesis of mammary epithelial cells. Cancer Res 2001:61:2301-6.
19. Brantiey-Sieders DM, Fang WB, Hwang Y, Hicks D, Chen J. Impaired tumor microenvironment in EphA2-deficient mice inhibits tumor angiogenesis and metastatic progression. FASEB J 2005:9:1884-6.
20. Lu M, Miller KD, Gokmen-Polar Y, Jeng MH, Kinch MS. EphA2 overexpression decreases estrogen dependence and tamoxifan sensitivity. Cancer Res 2003;63:3425-9.
21. Zelinski DP, Zantek ND, Walker-Daniels J, Peters MA, Taparowsky EJ, Kinch MS. Estrogen and Myc negatively regulate expression of the EphA2 tyrosine kinase. J Cell Biochem 2002;85:714-20.
22. Pan M. Overexpression of EphA2 gene in invasive human breast cancer and its association with hormone receptor status. J Clin Oncol 2005:23:9583.
23. Carles-Kinch K, Kilpatrick KE, Stewart JC, Kinch MS. Antibody targeting of the EphA2 tyrosine kinase inhibits malignant cell behavior. Cancer Res 1001;61:1840-7.
24. Cheng N, Brantlev DM, Liu H, Lin Q, Enriquez M, Gale N, Yanco-poulos G, Cerretti DP, Daniel TO, Chen J. Blockade of EphA2 receptor tyrosine kinase activation inhibits vascular endothelial cell growth factor-induced angiogenesis. Mol Cancer Res 2002; 1:2-11.
25. Cheng N, Brantley D, Fang W, Liu H, Fanslow W, Cerretti D, Bussell K, Reith A, Jackson D, Chen J. Inhibition of VEGF-dependent multistage carcinogenesis by soluble EphA receptors. Neoplasia 2003;5:445-56.
26. Dobrzanski P, Hunter K, Jones-Bolin S, Chang H, Robinson C, Pritchard S, Zhao H, Ruggeri B. Antiangiogenic and antitumor efficacy of EphA2 receptor antagonist. Cancer Res 2004;64:910-19.
27. Duxbury MS, Ito H, Ziimer MJ, Ashley SW, Whang EE. Ligation of EphA2 by Ephrin Al-Fc inhibits pancreatic adenocarcinoma cellular invasiveness. Biochem Biophys Res Commun 2004:320:1096-1102.
28. Brantley DM, Cheng N, Thompson EJ, Lin Q, Brekken RA, Thorpe PE, Muraoka RS, Cerretti DP, Pozzi A, Jackson D, Lin C, Chen J. Soluble Eph A receptors inhibit tumor angiogenesis and progression in vivo. Oncogene 2002;21:7011-26.
29. Wykosky J, Gibo DM, Debinski W. A novel, potent, specific ephrinA1 -based cytotoxin against EphA2 receptor expressing tumor ceils. Mol Cancer Ther 2007;6:3208-18.
30. Alves PMS, Faure O, Graff-Dubois S, Gross D-A, Cornet S, Chouaib S, Miconnet I, Lemonnier FA, Kosraatopoulos K. EphA2 as target of anticancer immunotherapy: identification of HLA-A*020l -restricted epitopes. Cancer Res 2003;63:8476-80.
31. Koolpe M, Dail M, Pasquale EB. An ephrin mimetic peptide that selectively targets the EphA2 receptor. J Biol Chem 2002;277:46974-9.
32. Noblitt LW, Bangari DS, Shukla S, Mohammed S, Mitral SK. Immunocompetent mouse model of breast cancer for preclinical testing of EphA2-targeted therapy. Cancer Gene Ther 2005:12:46-53.
33. Noblitt LW, Bangari DS, Shukla S, Knapp DW, Mohammed S, Kinch MS, Mitral SK. Decreased tumorigenic potential of EphA2-overex-pressing breast cancer cells following treatment with adenoviral vectors that express Ephrin A1. Cancer Gene Ther 2004; 11:757~66.
34. Yamaguchi S, Tatsumi T, Takehara T, Sakamori R, Uemura A, Mizushima T, Ohkawa K, Storkus WJ, Hayashi N. Immunotherapy of murine colon cancer using receptor tyrosine kinase EphA2-derived peptide-pulsed dendritic cell vaccines. Cancer 2007; 110:1469-77.
35. Kiewlich D, Zhang J, Gross C, Xia W, Larsen B, Cobb R, Biroc S, Gu J, Sato T, Light D, Heitner T, Willuda J, et al. Anti-EphA2 antibodies decrease EphA2 protein levels in murine CT26 colorectal and human MDA-231 breast tumors but do not inhibit tumor growth. Neoplasia 2006;8:18-30.
36. Larsen A, Pedersen M, Stockhausen M, Grandal M, van Deurs B, Poulsen H. Activation of the EGFR gene target EphA2 inhibits epidermal growth factor-induced cancer cell motility. Mol Cancer Res 2007;5:283-93.
37. Guo Ft, Miao H, Gerber L, Singh J, Denning MF, Gilliam AC, Wang B. Disruption of EphA2 receptor tyrosine kinase leads to increased susceptibility to carcinogenesis in mouse skin. Cancer Res 2006;66: 7050-8.
38. Macrae M, Neve R, Rodriguez-Viciana P, Haqq C, Yeh J, Chen C, Gray J. McCormick F, A conditional feedback loop regulates Ras activity through EphA2. Cancer Cell 2005:8:111-8.
39. Miao H, Wei B-R, Peehl DM, Li Q, Alexandrou T, Sehelling JR, Rhim JS, Sedor JR, Burnett E, Wang B. Activation of EphA receptor tyrosine kinase inhibits the Ras/MAPK pathway. Nat Cell Biol 2001;3:527-30.
40. Dohn M, Jiang J, Chen X. Receptor tyrosine kinase EphA2 is regulated by p53-family proteins and induces apoptosis. Oncogene 2001;20:6503-15.
41. Walker-Daniels J, Riese DJ, Kinch MS. C-Cbl-dependent EphA2 protein degradation is induced by ligand binding. Mol Cancer Res 2002; 1 ;79-87.
42. Wang Y, Ota S, Kataoka H, Kanamori M, Li Z, Band H, Tanaka M, SugimuraH. Negative regulation of EphA2 receptor by Cbl. Biochem Biophys Res Commun 2002;296:214-20.
43. Fang WB, Brantiey-Sieders DM, Parker MA, Reith AD, Chen J. A kinase-dependent role for EphA2 receptor in promoting tumor growth and metastasis. Oncogene 2005:24:7859-68.
44. Kosinski C, Li VSW, Chan AS, Zhang J, Ho C, Tsui WY, Chan TL, Mifflin RC, Powell DW, Yuen ST, Leung SY, Chen X. Gene expression patterns of human colon tops and basal crypts and BMP antagonists as intestinal stem cell niche factors. Proc Natl Acad Sci USA, 2007;104:15418-23.
45. Rosenberg IM, Goke M, Kanai M, Reinecker HC, Podolsky DK. Epithelial cell kinase-B61: an autocrine loop modulating intestinal epithelial migration and barrier function. Am J Physiol 1997:273:G824-G32.
46. Shao H, Pandey A, O'Shea KS, Seldin M, Dixit VM. Characterization of B61. the ligand for the Eck receptor protein-tyrosine kinase. J Biol Chem 1995;270:5636-41.
47. Saito T, Masuda N, Miyazaki T, Kanoh K, Suzuki H, Shimura T, Asao T, Kuwano H. Expression of EphA2 and E-cadherin in colorectal cancer with cancer metastasis. Oncol Rep 2004; 11:605-11.
48. Li Z, Tanaka M, Kataoka H, Nakamura R, Sanjar R, Shinmura K, Sugimura H. EphA2 up-regulation induced by deoxycholie acid in human colon carcinoma cells, an involvement of extracellular signal-regulated kinase and p53-independece. J Cancer Res Clin Oncol 2003:129:703-8.
49. Kataoka H, Tgarashi H, Kanamori M, Ihara M, Wang J, Wang Y, Li Z, Shiraamura T, Kobayashi T, Maruyaraa K, Nakamura T, Arai H, et al. Correlation of EPHA2 overexpression with high microvessel count in human primary colorectal cancer. Cancer Sci 2004;95:136-41.
50. Potla L, Boghaert ER, Armellino D, Frost P, Darale NK. Reduced expression of Ephrin-Al (EFNA1) inhibits three-dimensional growth of Ht29 colon carcinoma cells. Cancer Lett 2002;175:187-95.\
51. Min/+ mice. Oncogene 2008;27:3265-73.
52. Chen J, Nachabah A, Scherer C, Ganju P, Reith A, Bronson R, Ruley HE. Germ-line inactivation of the murine Eck receptor tyrosine kinase by gene trap retroviral insertion. Oncogene 1996;12:979-88.
53. AKR intestinal tumor resistance region consists of Pla2g2a and a locus distal to D4Mit64, Oncogene 2000; 19:3182-92.
54. Carothers AM, Javid SH, Moran AE, Hunt DH, Redston M, Bertagno-lii MM. Deficient E-cadherin adhesion in C57BL/6J-Min/+ mice is associated with increased tyrosine kinase activity and RhoA-dependent actomyosin contractility. Exp Cell Res 2006;312:387-400.
55. Carothers AM, Melstrom KA, Jr, Mueller JD, Weyant MJ, Bertagnolli MM. Progressive changes in adherens junction structure during intestinal adenoma formation in Apc mutant mice. J Biol Chem 2001;276:39094-102.
56. Misikangas M, Pajari AM, Paivarinta E, Mutanen M, Promotion of adenoma growth by dietary inulin associated with increase in cyclin Dl and decrease in adhesion proteins in Min/+ mice mucosa. J Nutr Biochem 2005:16:402-9.
57. Min/+ mice by (-)-epigallocatechin-3-gallate, the major catechin in green tea. Cancer Res 2005;65:10623-31.
58. Zantek ND, Azimi M, Fedor-Chaiken M, Wang B, Brackenbury R, Kinch MS. E-cadherin regulates the function of the EphA2 receptor tyrosine kinase. Ceil Growth Differ 1999;10:629-38.
59. Orsulic S. Kemler R. Expression of Eph receptors and ephrins is differentially regulated by E-cadherin. J Cell Sci 2000; 113:1793-1802.
60. Thelemann A, Petti F, Griffin G, Iwata K, Hunt T, Settinari T, Fenyo D, Gibson N, Haley JD. Phosphotyrosine signaling networks in epidermal growth factor receptor overexpressing squamous carcinoma ceils. Mol Cell Proteomics 2005;4:356-76.
61. Cortina C, Palomo-Ponce S, Iglesias M, Fernández-Masip JL, Vivancos A, Whissell G, Humá M,Peiró N, Gailego L, Jonkheer S, Davy A, Lloreta J, et al. EphB-ephrin-B interactions suppress colorectal cancer progression by compartmentalizing tumor cells. Nat Genet 2007;39:1376-83.